As presented in Table 1, the SLC2A10 expression level was significantly correlated with worse survival in several cancers, including brain cancer, breast cancer, lung cancer, colorectal cancer, eye cancer, skin cancer, and soft tissue cancer, while it was slightly correlated with worse survival in ovarian cancer. This evidence concerns the gene SLC2A10 and ovarian cancer.